Anticholinergic drugs exert their effects by blocking the action of acetylcholine at its receptor sites, particularly the muscarinic receptors in both the central and peripheral nervous systems. Structurally, anticholinergics are esters composed of an aromatic acid linked to an organic base. This ester linkage is crucial as it allows the drugs to effectively bind to acetylcholine receptors, where they act as competitive antagonists. By occupying these receptor sites, anticholinergics prevent acetylcholine from binding and initiating its physiological effects. This competitive inhibition blocks the downstream activation of second messengers, which are normally triggered upon acetylcholine binding and mediate various cellular processes such as smooth muscle contraction, secretion of glands, and modulation of heart rate.
Muscarinic receptors, the primary target of most anticholinergics, are not a homogeneous group but instead consist of several subtypes with varying locations and functions in the body. The muscarinic receptor subtypes include M1, M2, M3, M4, and M5 receptors, each playing a distinct role. For example, M1 receptors are primarily found in the central nervous system, autonomic ganglia, and gastric parietal cells, where they influence cognitive function, autonomic signaling, and gastric acid secretion. M2 receptors are located in the heart and play a role in slowing the heart rate (negative chronotropy), while M3 receptors are present in smooth muscles of organs like the bladder, gastrointestinal tract, and airways, controlling functions such as smooth muscle contraction and secretion. The degree to which anticholinergic drugs bind to these receptors can vary, which influences their therapeutic applications and side effects.
By blocking these receptors, anticholinergics diminish or completely halt the physiological actions normally mediated by acetylcholine. For instance, atropine, a widely used anticholinergic, binds predominantly to M2 receptors in the heart, preventing acetylcholine from inducing bradycardia. This is particularly useful during surgical procedures where excessive vagal stimulation can cause a dangerous drop in heart rate. In contrast, glycopyrrolate, another anticholinergic, is often used to reduce salivary and bronchial secretions by blocking M3 receptors in the glands and smooth muscles, making it useful during anesthesia to keep the airway clear.
Importantly, the therapeutic use of anticholinergics relies on their ability to selectively target certain muscarinic receptors while minimizing unwanted effects on others. For example, drugs like glycopyrrolate are designed to have minimal penetration of the blood-brain barrier, reducing the likelihood of central nervous system effects such as confusion or delirium, which can be problematic in elderly patients. This selective action makes glycopyrrolate a preferred choice in cases where peripheral effects are desired without affecting the brain.
The overall pharmacological action of anticholinergics depends not only on receptor subtype selectivity but also on the tissue distribution of those receptors. M1 receptors in the brain, M2 receptors in the heart, and M3 receptors in smooth muscle each contribute to the broad spectrum of effects seen with anticholinergic drugs. By understanding and leveraging these receptor dynamics, clinicians can effectively use anticholinergics to treat a range of conditions, from bradycardia and excessive secretions to asthma and gastrointestinal spasms, while managing potential side effects.
| Feature | Atropine | Glycopyrrolate | Scopolamine |
|---|---|---|---|
| Receptor emphasis | Binds predominantly M2 receptors in the heart | Blocks M3 receptors in glands and smooth muscle | — |
| Principal use in anesthesia | Prevents and treats bradycardia from vagal stimulation, including during intubation and surgical manipulation | Reduces salivary and bronchial secretions to keep the airway clear; given with neostigmine to block unwanted muscarinic effects during reversal | Prevention of motion sickness and as an adjunct to anesthesia |
| Blood–brain barrier | Crosses the barrier | Quaternary amine with minimal penetration | Tertiary amine that readily crosses |
| Central effects | Central effects possible; at higher doses agitation, confusion, delirium and seizures. Like other anticholinergics apart from scopolamine, it can cause CNS stimulation with restlessness, hallucinations or delirium, particularly in elderly patients and those with preexisting cognitive impairment | Unlikely, which makes it the preferred choice when peripheral effects are wanted without CNS involvement | CNS depression with sedation and amnesia |
| Cautions | Doses under 0.4 mg have been reported to cause paradoxical bradycardia; large doses can produce cutaneous vasodilation ("atropine flush") | — | — |
